TPG Asia is set to divest its entire 14.72% stake in Sai Life Sciences , a Hyderabad-based contract research and manufacturing organization, through a block deal valued at approximately ₹2,500 crore. The move comes as Sai Life Sciences reports strong financial performance and ambitious growth projections.

Block Deal Details

The proposed sale involves 3.07 crore shares with a floor price of ₹860 per share, representing a 5% discount to the last closing price. This strategic exit by TPG Asia marks a significant development for Sai Life Sciences and potential new investors.

Strong Financial Performance

Sai Life Sciences has demonstrated robust financial growth in its recent quarterly results:

The company's impressive performance was driven by substantial growth across its business segments:

• CDMO segment: 113% year-on-year growth
• Discovery revenues: 38% year-on-year growth

Future Outlook

Sai Life Sciences has set ambitious targets for the coming years:

• Projected revenue growth: 15-20% annually over the next three to five years
• Margin expansion targets: 24-30%

These projections indicate the company's confidence in its business model and market position.

Market Response

Despite the positive financial results and growth outlook, Sai Life Sciences' shares closed at ₹905.90, down 2.16%. This slight dip may be attributed to the news of TPG Asia's impending exit and the proposed discount on the block deal price.

The block deal announcement and Sai Life Sciences' strong financial performance present an interesting scenario for investors. As TPG Asia prepares to exit, the market will be watching closely to see who steps in to acquire this significant stake in a rapidly growing contract research and manufacturing organization.

Sai Life Sciences , a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), has announced the reappointment of Krishnamraju Kanumuri as Managing Director and CEO for a five-year term, along with its financial results for the first quarter of fiscal year 2026.

Leadership Continuity

The Board of Directors of Sai Life Sciences approved the reappointment of Krishnamraju Kanumuri as Managing Director & CEO for a term of five years, effective from September 1, 2025, to August 31, 2030. This decision, made during the board meeting held on August 7, 2025, is subject to shareholder approval at the upcoming Annual General Meeting scheduled for September 11, 2025.

Kanumuri, who has been with the company since 2004, has played a pivotal role in transforming Sai Life Sciences from a domestic service provider into a globally respected CRDMO. Under his leadership, the company has achieved significant milestones, including:

• A 25% revenue CAGR from 2022 to 2025
• Expansion of global footprint with R&D centers in Boston and Manchester
• Successful completion of the company's IPO in December 2024

Q1 FY2026 Financial Highlights

Sai Life Sciences also reported robust financial results for the quarter ended June 30, 2025:

The company demonstrated strong year-over-year growth, with revenue from operations increasing by 77.50% compared to the same quarter in the previous fiscal year. Sai Life Sciences also returned to profitability, reporting a profit after tax of ₹604.55 million for the quarter.

Earnings Per Share

The earnings per share (EPS) for Q1 FY2026 stood at:

• Basic EPS: ₹2.90 (not annualized)
• Diluted EPS: ₹2.83 (not annualized)

This marks a significant improvement from the loss per share reported in Q1 FY2025.

Annual General Meeting

The company announced that its 26th Annual General Meeting will be held on Thursday, September 11, 2025, at 10:30 AM (IST) through Video Conferencing / Other Audio-Visual Means.

Sai Life Sciences continues to operate in a single segment of providing Contract Research, Development, and Manufacturing (CRDMO) services, catering to pharmaceutical and biotech innovators globally. The reappointment of Krishnamraju Kanumuri and the strong financial performance indicate the company's commitment to sustained growth and leadership in the CRDMO space.